Tandem’s t:slim X2 insulin pump connected to the Dexcom G5 CGM was approved by the FDA in August, 2017. The Dexcom G5 is currently the most accurate CGM on the market and will soon be followed by the G6 CGM that will have greater accuracy, no Tylenol interference, and may eventually require no calibrations. Besides the simplicity of its color touchscreen interface, the X2 is the first and only pump that allows remote software updates. This allows users to automatically upgrade the pump software without waiting for their insurance to approve a new pump body 4 to 5 years later.
The FDA approved the Medtronic 670G Hybrid Closed Loop System in September of 2016. It was the first device approved by the FDA that can automatically monitor blood sugars and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes.
Tandem has announced their newest pump, the t:slim X2. This update to the t:slim Insulin Pump has improved bluetooth capabilities and works with the Tandem Device Updater for remote software updates from a personal computer. The addition of the bluetooth radio will allow future devices and applications to "talk" directly to the pump. The Tandem Device Updater allows users to update the software on their pumps without purchasing a replacement unit. It has the potential to enable users to add new features without worrying about normal insurance pump replacement cycles.
Minimed received FDA approval for its 670G system in September 2016. Expected to ship in Spring of 2017, the 670G automatically adjusts the delivery of your basal insulin based on readings from Minimed's new CGM, the Guardian Sensor 3 and the Guardian Link 3 transmitter. The sensors are said to have a 7-day life span while being continuously monitored by their new diagnostic technology that monitors how the sensor is doing. This is currently the only sensor approved to drive the amount of insulin delivered by a pump.
When a pump company brings out a new pump, wearers using the prior models often want to upgrade to the latest and greatest device for its advancements or improvements in software or hardware. And based on usual industry practice, they expect an upgrade policy that allows them to buy the new pump at a reduced price. Tandem Pump Company recently announced the good news that FDA approval for the new t:slim G4 insulin pump that comes with a built-in Dexcom G4 is expected later this year. This new pump has a new body, new software, and new parts that allow it to display Dexcom G4 data right on the pump screen. Tandem will be ready to ship 30 days after approval.
The Apple Watch and its operating system iOS 8 holds great promise for people with diabetes when it and the iPhone finally connect wearers to Apple’s Health software. With Android options also rapidly developing, these advances hold great potential for easy passage of diabetes data between devices so it can benefit people with diabetes and their health care providers. The question we really want answered is when will the meter, pump and CGM talk to each other?
A provocative article on the front page of the Sunday’s New York Times (April 6, 2014) took on the high cost of diabetes care and investigated several areas of medical advancements as well as outrageous pricing. The article asks startling questions such as: Are your favorite diabetes drugs and devices relevant to your treatment?